Literature DB >> 22313792

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.

Paolo Montaldo1, Lucia Tafuro, Monica Rea, Valeria Narciso, Azzurra C Iossa, Roberto Del Gado.   

Abstract

OBJECTIVES: To assess the efficacy of desmopressin plus oxybutynin and compare two starting dosages of desmopressin (120 and 240 µg) in a randomized, double-blinded, placebo-controlled trial for children with monosymptomatic nocturnal enuresis (MNE) resistant to desmopressin. The predictive factors of children with MNE responsive to desmopressin and combination therapy were also evaluated. PATIENTS AND METHODS: Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males. All patients were required to have MNE. The patients were randomly divided into two groups: the first group was given oral melt 120 µg and the second group 240 µg, for 2 weeks. All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks. As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered.
RESULTS: There was no significant difference between the 120 µg and 240 µg patients in terms of response. The oxybutynin group showed a higher rate of full and partial responses (45% success) compared with the placebo group (17% success), P < 0.01. The responders to combined oxybutynin and desmopressin had significantly lower bladder volume and wall thickness index than the other patients.
CONCLUSIONS: Our findings highlight that anticholinergic agents may play an important role for a subset of children with enuresis who have a restricted bladder capacity and thickened bladder wall. Ultrasonography-measured bladder variables can provide useful predictive clues for MNE. Predictive factors can help to differentiate treatment subtypes and guide clinical management in primary nocturnal enuresis.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313792     DOI: 10.1111/j.1464-410X.2011.10918.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Desmopressin alone versus desmopressin and an anticholinergic in the first-line treatment of primary monosymptomatic nocturnal enuresis: a multicenter study.

Authors:  Se Jin Park; Ji Min Park; Ki Soo Pai; Tae Sun Ha; Sang Don Lee; Minki Baek
Journal:  Pediatr Nephrol       Date:  2014-01-30       Impact factor: 3.714

2.  Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial.

Authors:  Myungsun Shim; Woo Jin Bang; Cheol Young Oh; Min Jae Kang; Jin Seon Cho
Journal:  Investig Clin Urol       Date:  2021-03-16

3.  Alarm interventions for nocturnal enuresis in children.

Authors:  Patrina Hy Caldwell; Miriam Codarini; Fiona Stewart; Deirdre Hahn; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

4.  Desmopressin, Imipramine, and Oxybutynin in the Treatment of Primary Nocturnal Enuresis: A Randomized Clinical Trial.

Authors:  Maryam Seyfhashemi; Raheb Ghorbani; Abbas Zolfaghari
Journal:  Iran Red Crescent Med J       Date:  2015-07-01       Impact factor: 0.611

5.  Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis.

Authors:  Anoush Azarfar; Mohammad Esmaeili; Mitra Naseri; Fatemeh Ghane; Yalda Ravanshad; Marjan Vejdani; Neda Ghanei; Akbar Babaei-Heydarabadi; Seyed-Ehsan Saffari
Journal:  J Renal Inj Prev       Date:  2015-09-01

6.  Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial.

Authors:  Kambiz Ghasemi; Maryam Esteghamati; Malihe Mohammadzadeh; Shahram Zare
Journal:  Electron Physician       Date:  2016-03-25

7.  Desmopressin plus anticholinergic agent in the treatment of nocturnal enuresis: A meta-analysis.

Authors:  Jianyong Yu; Zhaojun Yan; Shiying Zhou; Feng Han; Feng Xiao; Jian Han; Congling Sun
Journal:  Exp Ther Med       Date:  2017-08-07       Impact factor: 2.447

8.  A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial.

Authors:  Parvin Mousavi Ghanavati; Dinyar Khazaeli; Mohammadreza Amjadzadeh
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.